Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

US Biotech Regeneron Pharmaceuticals today announced financial results for the second quarter of 2025 and provided a business ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and ...

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, July 29, 2025, to ...

Over 100 prominent companies are currently engaged in developing treatments for osteoarthritis. Among them, Biosplice Therapeutics has drug candidates that have reached the most advanced stage—Phase ...

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...